Generic Fanapt Availability
Last updated on Apr 10, 2025.
Fanapt is a brand name of iloperidone, approved by the FDA in the following formulation(s):
FANAPT (iloperidone - tablet;oral)
-
Manufacturer: VANDA PHARMS INC
Approval date: May 6, 2009
Strength(s): 1MG [RLD], 2MG [RLD], 4MG [RLD], 6MG [RLD], 8MG [RLD], 10MG [RLD], 12MG [RLD]
Is there a generic version of Fanapt available?
No. There is currently no therapeutically equivalent version of Fanapt available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fanapt. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Methods for the administration of iloperidone
Patent 8,586,610
Issued: November 19, 2013
Inventor(s): Wolfgang Curt D. & Polymeropoulos Mihael H.
Assignee(s): Vanda Pharmaceuticals, Inc.The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.
Patent expiration dates:
- November 2, 2027✓
- November 2, 2027
-
Prediction of QT prolongation based on SNP genotype
Patent 8,652,776
Issued: February 18, 2014
Inventor(s): Lavedan Christian & Volpi Simona & Licamele Louis & Mack Kendra Tomino & Heaton Callie Michelle
Assignee(s): Vanda Pharmaceuticals, Inc.The present invention relates to the prediction of QT prolongation following administration of a compound capable of increasing an individual's QT interval based on the individual's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction.
Patent expiration dates:
- August 31, 2030✓
- August 31, 2030
-
Method of treatment based on polymorphisms of the KCNQ1 gene
Patent 8,999,638
Issued: April 7, 2015
Inventor(s): Wolfgang Curt D. & Polymeropoulos Mihael H.
Assignee(s): Vanda Pharmaceuticals, Inc.The invention provides methods for the administration of compounds capable of prolonging a QTc interval and methods for predicting whether an individual is predisposed to such QTc prolongation.
Patent expiration dates:
- October 28, 2030✓
- October 28, 2030
-
Method of predicting a predisposition to QT prolongation
Patent 9,072,742
Issued: July 7, 2015
Inventor(s): Lavedan Christian & Volpi Simona & Licamele Louis
Assignee(s): Vanda Pharmaceuticals, Inc.The present invention describes an association between genetic polymorphisms in the BAI3 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
Patent expiration dates:
- January 16, 2031✓
- January 16, 2031
-
Method of predicting a predisposition to QT prolongation
Patent 9,074,254
Issued: July 7, 2015
Inventor(s): Lavedan Christian & Volpi Simona & Licamele Louis & Mack Kendra Tomino & Heaton Callie Michelle
Assignee(s): Vanda Pharmaceuticals, Inc.The present invention describes an association between genetic polymorphisms in the ceramide kinase-like (CERKL) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
Patent expiration dates:
- December 28, 2031✓
- December 28, 2031
-
Method of predicting a predisposition to QT prolongation
Patent 9,074,255
Issued: July 7, 2015
Inventor(s): Lavedan Christian & Volpi Simona & Licamele Louis
Assignee(s): Vanda Pharmaceuticals, Inc.The present invention describes an association between genetic polymorphisms in the FAM13A1 (family with sequence similarity 13, member A1) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval- prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
Patent expiration dates:
- December 17, 2030✓
- December 17, 2030
-
Method of predicting a predisposition to QT prolongation
Patent 9,074,256
Issued: July 7, 2015
Inventor(s): Lavedan Christian & Volpi Simona & Licamele Louis
Assignee(s): Vanda Pharmaceuticals, Inc.The present invention describes an association between genetic polymorphisms in the ABCC2 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
Patent expiration dates:
- February 10, 2031✓
- February 10, 2031
-
Methods for the administration of iloperidone
Patent 9,138,432
Issued: September 22, 2015
Inventor(s): Wolfgang Curt & Polymeropoulos Mihael
Assignee(s): Vanda Pharmaceuticals, Inc.The present invention relates to methods for treating a patient with iloperidone or a metabolite thereof, which patient is also being treated with fluoxetine, and lowering risk for QT prolongation.
Patent expiration dates:
- September 30, 2025✓
- September 30, 2025
-
Method of treatment based on polymorphisms of the KCNQ1 gene
Patent 9,157,121
Issued: October 13, 2015
Inventor(s): Wolfgang Curt D. & Polymeropoulos Mihael H.
Assignee(s): Vanda Pharmaceuticals, Inc.The invention provides methods for the administration of compounds capable of prolonging a QTc interval and methods for predicting whether an individual is predisposed to such QTc prolongation.
Patent expiration dates:
- April 5, 2030✓
- April 5, 2030
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- April 2, 2027 - INDICATED FOR ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN ADULTS
More about Fanapt (iloperidone)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (30)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: atypical antipsychotics
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
